Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice. (Q50509855)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 May 2012

Language	Label	Description	Also known as
English	Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.	scientific article published on 18 May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

F Vittone

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A Liberman

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

D Vasic

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

R Ostertag

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Esser

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

D Walcher

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

N Marx

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Burgmaier

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

18 May 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

55

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2267-2275

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22648661%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

https://scigraph.springernature.com/pub.10.1007/s00125-012-2582-5

0 references

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Sitagliptin (MK0431) inhibition of dipeptidyl peptidase IV decreases nonobese diabetic mouse CD4+ T-cell migration through incretin-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Dyslipidemia inhibits Toll-like receptor-induced activation of CD8alpha-negative dendritic cells and protective Th1 type immunity

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Sequence, purification, and cloning of an intracellular serine protease, quiescent cell proline dipeptidase

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

C-peptide colocalizes with macrophages in early arteriosclerotic lesions of diabetic subjects and induces monocyte chemotaxis in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

The Physiology of Glucagon-like Peptide 1

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Glucagon-like peptide-1 inhibits LPS-induced IL-1beta production in cultured rat astrocytes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

CD26/dipeptidyl-peptidase IV in psoriatic skin: upregulation and topographical changes.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Current advances and therapeutic potential of agents targeting dipeptidyl peptidases-IV, -II, 8/9 and fibroblast activation protein

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

SDF-1 (CXCL12) in haematopoiesis and leukaemia: impact of DPP IV/CD26.

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Diabetes and atherosclerosis: epidemiology, pathophysiology, and management

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Atherosclerosis — An Inflammatory Disease

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS00125-012-2582-5

21 January 2018

Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22648661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incretins: a new treatment option for type 2 diabetes?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22648661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Molecular characterization of dipeptidyl peptidase activity in serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/22648661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/22648661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor

1 reference

https://pubmed.ncbi.nlm.nih.gov/22648661

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q50509855&oldid=1413687013"